A phase II clinical trial of idarubicin administered to children with relapsed brain tumors Academic Article Article uri icon

Overview

MeSH Major

  • Heart Defects, Congenital

abstract

  • IDR, given at a dose of 5 mg/m2/day x 3 days, is not sufficiently active against relapsed medulloblastoma, ependymoma, or brain stem tumors to warrant further study of this agent in a Phase III setting. The response rate for patients with relapsed high grade astrocytoma was 15% (95% confidence interval, 3.3-40%).

publication date

  • August 15, 1998

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1002/(SICI)1097-0142(19980815)83:4<813::AID-CNCR27>3.0.CO;2-U

PubMed ID

  • 9708950

Additional Document Info

start page

  • 813

end page

  • 6

volume

  • 83

number

  • 4